
ã³ããã¯ã¯ãã³åŸéºç被害è ã®Kenããã»æ±æžå·ç é¢ã§DFPP+幹现èå¹é€äžæž 液治çãåããçµæ
PRE AND POST TREATMENT CHEST X RAYS
â KenCaptn20114 (@KenCaptn20114) May 19, 2026
You can see the clots covering my entire chest and the massive heart inflammation pic.twitter.com/Swnup5LYGJ
UPDATE POST TREATMENT
â KenCaptn20114 (@KenCaptn20114) May 19, 2026
PATIENT # 14 KEN EVANS
Kevin McCairn DFFP and SGF treatment program
This is a self-assessment directed at friends, family, acquaintances, and my doctors. There are still so many non-believers, non-interested, or do not cares out there, even in my family. If⊠pic.twitter.com/d9qccSW3Sv
æ²»çåŸã®ç¶æ³å ±å
æ£è çªå·14ïŒã±ã³ã»ãšãã³ã¹
ã±ãã³ã»ãã±ã¢ã³ DFFP ããã³ SGF æ²»çããã°ã©ã
ããã¯ãå人ãå®¶æãç¥äººããããŠç§ã®äž»æ²»å»ã«åããèªå·±è©äŸ¡èšé²ã ãç§ã®å®¶æã®äžã«ãããããŸã ã«ä¿¡ããªãè ãç¡é¢å¿ãªè ãæ°ã«çããªãè ãããŸãã«å€ãååšãããç§ãç¥ãè ã¯ãã©ãããããèªãã§ã»ãããããããã°ãåã話ã100äžåãç¹°ãè¿ããã«æžããããã¯ãå¥åº·ãCOVIDãã¯ã¯ãã³åŸéºçããããŠçã«ã€ããŠç§ãåŠãã ããšã§ããã
ãªãåŠçœ®ãå¿ èŠã ã£ãã®ã
ç§ã¯ãã¡ã€ã¶ãŒè£œã®ã¯ã¯ãã³ãšããŒã¹ã¿ãŒæ¥çš®ã«ãããè¡æ ããã¹ãã©ãŒã«ãã£ã³ã°ã¿ã³ãã¯è³ªããããŠèªå·±æäœã«å šèº«ãèŠãããŠãããããªãŒãºãžé£ãã«è¡ãäºå®ã ã£ãããã¯ã¯ãã³ãææ°ã®ç¶æ ã§ãªããã°åºçºãèš±å¯ãããªãã£ãã®ã ãæ¥çš®ã«ããã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯ãè¡ç®¡ç³»ãç®åãã«å šèº«ãé§ãå·¡ã£ããã¹ãã€ã¯ã¿ã³ãã¯è³ªãšã¢ããã€ãã¯ãããããèåšãäžæ¢ç¥çµç³»ãè³ãå«ãäœã®å šçµç¹ã«çªãåºãã£ããçµç¹ããåºè¡ããç®èã«ã¯ç©ŽãéããŠæœ°çã«ãªãã錻ããã¯è¡ã®æ··ãã£ããããã¿ãèºããã¯è¡ç°ãåºãã䟿ãèãé£éãããåºè¡ããã£ããèªå·±å ç«æ§èçãšèšºæãããé£éã«ã¯ç©ŽãéããŠãããèèãèºãå·Šè èã«ã¯ç·ç¶åãèŠã€ãããèŸè «ïŒèŸèã®è «ãïŒãšã蚺æãããã
å¿èã¯ããããã ãæåã¯å¿ççãå¿èçãæ°å¹Žéã®é »èãç¶ãããã®åŸãå¿çå¿èçãžãšé²è¡ãããçæ€ã®çµæãç·ç¶åãšç¢çã埮å°è¡ç®¡çŸæ£ã倿ããå¿èã®æåã¯æ¥µããŠåŒ±ãŸã£ãŠãããå¿ææ°ã¯190bpmãŸã§è·³ãäžãã£ãããšæãã°ã40bpmãŸã§æ¥èœãããè¡å§ã¯220/160ãŸã§ççºçã«äžæããç§ãæã¡ã®ããããäœåºŠãäœåºŠãææ¥å€æ¥ãžéã£ãããã€ãã«éãã®ãããããäžæ¢ç¥çµç³»ãæ»æãåããå³èãšè¶³ã麻çºããã蚺æã¯å°ç¹ç¶ãã¥ãŒããããŒïŒSFN-2ïŒã§ãã£ããå åæ³ç³»ãæ©èœããªããªããåŒåžãã§ããªããªã£ãããããªãŒãé€å»ã®æè¡ãåããããããã4é±éåŸã«å¯éŒ»è ã¯å®å šã«ééãããä»ã§ã¯ãããMCASïŒè¥æºçŽ°èæŽ»æ§åçå矀ïŒã§ãã£ããšåãã£ãŠãããå»åž«ã¯ã«ããžã®æé²ãçããç§ã¯ãã®èª¿æ»ã«æ²¡é ãããç²ç¶è ºã¯æ©èœäº¢é²ç¶æ ã«ãªããå»åž«ã«å§ãããããŸãŸæåºãããç¡ç¥ãªå»åž«ã«ãããã®èª€èšºã¯ãç§ã®äººçã§ææªã®éã¡ãšãªã£ããä»ãç§ã¯ç²ç¶è ºããªãç¶æ ã§ãæ¯æ¥æ©æ¬ç ã®çç¶ãšéã£ãŠããããããé©ãã¹ãããšã«ãç§ã®å åæ³å°éå»ã¯ãã¯ã¯ãã³æ¥çš®è ã¯èšºå¯ããªãããšèšãã®ã ã
ããã«èªå·±å ç«æ§è³çïŒè³ã®è «ããCASPR-2èªå·±æäœïŒãçºçããè³é害ãèãé£ãçã¿ãè «ãããã¬ã€ã³ãã©ã°ãèªç¥æ©èœã®äœäžãæãããææ ãæããèœåã¯å€±ããããŸãã§ãã±ããé ã«è¢«ãããããããªãéé¢ãããæèŠã«é¥ã£ããæ³åãçµ¶ããç²åŽæãšãã¬ã€ã³ãã©ã°ã ãæ€ åã«åº§ã£ãŠããéãæã§é ãæ¯ããŠããªããã°ãªããªãããšãããã£ãã2023幎ã«ã¯å®å šã«æ£åžžã ã£ãè³ã®MRIã ãã2025幎ã«ã¯è³å šäœã«æ£åšããçœè³ªç å€ãæ€åºãããã骚é«çæ€ã®åã«çãå æããããšãMDã¢ã³ããŒãœã³ã§ã€ãã«ã¡ã¯ãã³ãšãã§ã³ãã³ããŸãŒã«ãæçšãç¶ããã
ç§ãçãå»¶ã³ãããšããŸããŠãæ¥æ¬ã«æ¥ãããããšèªäœãå¥è·¡ã ãæ¥æ¬ã«æ¥ããŸã§ç¥ããªãã£ãããšã ããç§ã¯äœåºŠããµã€ãã«ã€ã³ã¹ããŒã ã«é¥ã£ãŠãããå¿ææ°ã190ãè¶ ãã40以äžã«æ¥èœãããã³ã«åšå²ã¯æ»ãèŠæããããç§ã¯çãæããã®ã ã
ãªããããèµ·ãã誰ã«è²¬ä»»ãããã®ã
äœå ã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªã¯åæ¢ããããšãªããã¢ããã€ãè¡æ ã圢æãç¶ãããç§ã®å ç«ç³»ã¯ãããã®éšäœãæ»æããç¢çãæå®³ãªèªå·±æäœããããŠå šèº«ãæ¿ããæå·ãããç°åžžã¿ã³ãã¯è³ªãæ®ããã3åã®æ¥çš®ã§120å åã®ã¹ãã€ã¯ååãæ³šå ¥ããããã®åŸã®ææã§ããã«è¿œå ããããç§ã®äœã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªå·¥å Žããšåããäœãããã°äœãããã»ã©è¡æ ã圢æãããã®ã ã
ãã¡ã€ã¶ãŒã¯ãã¯ã¯ãã³ã«ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ããªãã¹ã€ããããçµã¿èŸŒãŸãªãã£ãããã®ã¯ã¯ãã³ã¯ææãäŒæãé²ããªãã£ãã圌ãã¯æå¹æ§ããŒã¿ãæé ããŠäººã ãæ¬ºããããã¡ã€ã¶ãŒãšã¢ãã«ãèªèº«ã®ç ç©¶ãèŠãã°ã補åã圹ã«ç«ããªãããšïŒæå¹æ§0.084%ïŒãèªãèªããŠããã圌ãã¯ããŒã¿ãããæ²ããŠå šå¡ãéšããã®ã ã圌ããç ç©¶ã§å ¬è¡šããã¯ã¯ãã³ãšãå®éã«é åžããããã®ã¯å¥ç©ã§ãã£ãããã³ãããã¯æã圌ãã¯ã¯ã¯ãã³ã®æºåãã§ããŠããªãã£ããããå·å庫ã®å¥¥ãããå®éšçšã©ããã«è «çãäœãããã«äœ¿çšããããSV40ããåŒã£åŒµãåºããã¯ã¯ãã³ã«äœ¿çšãããããã ããã®éãã ããããŠããããé ãããã«æ·»å ç©ãçšãããç ç©¶å®äºåŸã圌ãã¯èŽåœçãªãã©ã¹ããDNAãæ·»å ãããããäžçäžã«é åžããŠå€§éã®è² å·ãšæ»ãæããã
æ¿åºã¯2012幎ã«ãæ¿åºåºè³ã®DARPAãéããŠCOVIDãäœãåºããããã¡ãŠãããããåŒãç¶ããç±³åœãè³éãæäŸããããã¡ãŠãã¯6人ã®ç§åŠè ã«éãæãããŠã€ã«ã¹ã®èµ·æºã«ã€ããŠåãã€ããããç±³åœã¯çºçæºã§ããäžåœãšã身代ãããšããŠã®ãã¡ãŠããå®ã£ãããã¡ã€ã¶ãŒã¯åæ¥ããæ»äº¡ããŒã¿ãé èœããŠãããæ»è ãå¢ããã»ã©ã圌ãã¯é èœã«å·çããããã®åŸãCDCãNIHãFDAããã¹ãŠã®ããŒã¿ãåãç«ãŠãæ»ãéçã®ã·ã°ãã«ãé ãå§ãããåã«åãéããæ§ã¯ããŸãã«ç¯çœªè ã§ããã
èçãå¿ èŠãšãªã£ãèµ€ã¡ããã®è¡äžããããç§ãšåããããªã¢ããã€ãè¡æ ãèŠã€ãã£ãŠããããã¡ã€ã¶ãŒã®ç ç©¶ã§ã¯ãåŠåš äžã®å¥³æ§ã®82%ãèµ€ã¡ããã倱ã£ããã圌ãã¯ãããé ãããCDCã®ããŒã¿ã§ã¯12äžäººã®åäŸãæ»äº¡ããããšã瀺ãããããéåžžãå ±åãããã®ã¯å šäœã®1%ã«éããªãããããã®æ³šå°ãããŸã ã«æµéããŠããããšã¯ç¯çœªã ããã©ã³ããšã±ããã£ã¯ãã®ä»¶ãäžçèè² ãããšã«ãªãã圌ãã®2幎éã®ä»»æäžã«700äžäººã®åäŸãæ¥çš®ãåããã
2023幎ã«ã¯çãççºçã«å¢å ãããCDCã¯æ°åãããŸãã«é ·ãã£ããããçããŒã¿ã®å ¬è¡šã極éãŸã§é ãããã2024幎ãš2025幎ã®ããŒã¿ã¯ç Žæ» çãªãã®ã«ãªãã ãããã¯ã¯ãã³ãæã£ãè ã¯çã®ãªã¹ã¯ããããããã¯äœå ã®NK现èãT现èããããŠP53ïŒçæå¶çްèïŒãæžå°ãããããã ãã ãããããã¿ãŒãçããçåšãæ¯ãã£ãŠãããäœå ã®çްèãå€è³ªããŠããŸã£ãã®ã ã
æ²»çå 容
åŠçœ®ã¯ãè³ããæ»ãè¡æ¶²ãæããããã«é žéèã«ã«ããŒãã«ãæ¿å ¥ããããšããå§ãŸã£ããé žéèãéãããšã§ãçæéã§å€§éã®è¡æ¶²ããéããããšãå¯èœã«ãªãããã£ã«ã¿ãŒã§è¡æ¶²ãšè¡æŒ¿ãåé¢ãããè¡æŒ¿ã¯10幎以äžåãã䜿çšãããŠããç¹æ®ãªãã£ã«ã¿ãŒãééããèªå·±æäœãç°åžžã¿ã³ãã¯è³ªãé€å»ããããã¹ãã€ã¯ã¿ã³ãã¯è³ªãè¡æ ãé€å»ãããã®ã¯å€§ããªå¯ç£ç©ã ã
ãéã¯é±ã«1åè¡ãããããã以å€ã®æ¥ã¯ãSGFïŒä¹³æ¯ç±æ¥ã®å¹¹çްèäžæž æ¶²ïŒã®ç¹æ»Žãåãããæ³šå ¥ãããSGFã¯ç§èªèº«ã®å¹¹çްèãæŽ»æ§åãããäœå ã®æå·ã修埩ãå§ãããããéããšãå¹¹çŽ°èæŽ»æ§åãããããæäŸãããŠããå Žæã¯ãäžçã§æ¥æ¬ã ãã§ããã
çµæ
ç§ã¯çããŠãããæ°åããã£ãšè¯ããç¬ãã幞ããæããŠãããéå»5幎éãç§ã®QOLã¯çç¡ã ã£ããèªåã®äººçãåäººãæŽ»åçãªæ¥ã ã倱ã£ãŠããã4é±éã®æ²»çã§ãã¹ãã€ã¯æäœã¬ãã«ã25%æžå°ãããããã¯ãµããªã¡ã³ãã§ã¯æ°å¹Žä»¥äžãããæ°å€ã ããã¬ã€ã³ãã©ã°ãèªç¥çã®ãããªçç¶ãææ ã®åªå€±ã¯å®å šã«æ¶ãå»ã£ããç§ã®è³ã¯èªç±ã§ã¯ãªã¢ã ãä»ãç§ã¯äººçã®ããããäºçްãªããšã«æè¬ããã¹ãã¬ã¹ãæé€ããããšããŠãããéå»5幎éã®èŠãã¿ã¯åãŸãããã®ã ã£ããããåºè¡ããåããªããªããããªåçºããªãããã ãæ®éã«è¿ãæèŠãšãå°ãã®ç²ããããã ãã ã
ä»åŸã«ã€ããŠ
ç§ã¯ãã®è©Šéšçæ²»çãåãã14çªç®ã®æ£è ã ã£ããæ£è ã°ã«ãŒãã代衚ããŠèšãã°ãã¹ãã€ã¯ãè¡æ ãåçºãããã©ããã¯ãŸã åãããªããæã ã¯ãµããªã¡ã³ããæåããè¡æ¶²ãæ³šææ·±ãç£èŠããŠãããæ²»çåŸãæ²»çãæ©ããããã«SGFã®ç¹éŒ»è¬ãæã¡åž°ãããšãã§ãããç§ã¯å¯ãããã ã£ãæ£è ãæ¯ãå¹ãè¿ããæ¥µããŠéçã ã£ã人ã ãå埩ããã®ãèŠãŠãããç§ã«ã¯ãŸã å€ãã®çŸæ£ãæ®ã£ãŠããããå¿é ã¯ããŠããªããç§ã¯çããŠãããæ°ããäžæ¥ãè¿ããŠãããéã®ãã¯é·ãããããã«ããããããšãå¬ããæãã
æ²»çåã®è¡æ¶²ãµã³ãã«
以äžã¯ãç§ã®æ²»çåã®è¡æ¶²ãµã³ãã«ã ãäžæ»Žã®è¡æ¶²ã®äžã«æ±æç©è³ªãèŠããããã¢ããã€ãè¡æ ã糞ç¶ã®ã¯ã©ã¹ã¿ãŒïŒãã£ããªã«ïŒããããŠæåã®åçã®å·Šäžã«ã¯ã«ã¹ã±ãŒãïŒé£éåå¿ïŒã確èªã§ããã



PRE AND POST TREATMENT CHEST X RAYS
â KenCaptn20114 (@KenCaptn20114) May 19, 2026
You can see the clots covering my entire chest and the massive heart inflammation pic.twitter.com/Swnup5LYGJ
æ²»çååŸã®èžéšãšãã¯ã¹ç·åç
ç§ã®èžéšå šäœãèŠãè¡æ ãšãåãŸããå¿èã®ççãèŠãŠåããã¯ãã ã



BEFORE AND AFTER SPIKE ANTIBODY TESTS pic.twitter.com/KAqKRxQZJi
â KenCaptn20114 (@KenCaptn20114) May 19, 2026

ã¢ããããŒããããæ€æ»çµæã®ç»åããèªã¿åããæ°å€ã®æšç§»ãšãæçš¿è ã®èšè¿°ïŒã4é±éã®æ²»çã§ã¹ãã€ã¯æäœã¬ãã«ã25%æžå°ãããïŒãšã®æŽåæ§ãæ¯èŒããæèŠã¯ä»¥äžã®éãã ã
1. æ€æ»ããŒã¿ã®æ°å€ãšæç³»åã®ç¢ºèª
ç»åã«ç€ºãããŠããæ€æ»çµæã¯ãåºæºå€ïŒReference IntervalïŒã Negative < 0.8 U/mL ãšãããŠãããéåžžã«é«ãæäœäŸ¡ãèšé²ãããŠãããæç³»åé ïŒå€ãé ïŒã«æ°å€ã䞊ã¹ããšä»¥äžã®ããã«ãªãã
2025幎03æ08æ¥ïŒ 16,701 U/mL
2025幎04æ25æ¥ïŒ 16,196 U/mL
2025幎09æ11æ¥ïŒ 17,900 U/mLïŒâ»ããã§æé«å€ãèšé²ïŒ
2026幎03æ24æ¥ïŒ 15,850 U/mL
2026幎05æ05æ¥ïŒ 11,971 U/mL ïŒææ°çµæïŒ
2. ãæ²»çåããšãæ²»çåŸãã®æ¯èŒïŒæ€èšŒïŒ
æçš¿è ã¯æ¬æäžã§ã4é±éã®æ²»çã§ã¹ãã€ã¯æäœã¬ãã«ã25%æžå°ããããšè¿°ã¹ãŠããããã®äž»åŒµãææ°ã®ããŒã¿éã§èšç®ã»æ€èšŒããã
æ²»çåïŒçŽè¿ïŒïŒ 2026幎3æ24æ¥ã®æ°å€ 15,850
æ²»çåŸïŒææ°ïŒïŒ 2026幎5æ5æ¥ã®æ°å€ 11,971
ãæžå°çã®èšç®ã
çŽè¿ã®ã15,850ãããææ°ã®ã11,971ããžã®æžå°å¹ 㯠3,879 ã§ããã
ãããããŒã»ã³ããŒãžã«æç®ãããšã
3,879 ÷ 15,850 à 100 ïŒ çŽ 24.47%
ãšãªããçŽ24.5%ã®æžå°ã確èªã§ããã
æéãšããŠãã3æ24æ¥ãããã5æ5æ¥ããŸã§ã®çŽ6é±éïŒ1ã¶æåïŒã®éã«ãã®æžå°ãèµ·ããŠãããKenã䞻匵ããã4é±éã®æ²»çã«ãã25%ã®æžå°ããšããå 容ãšãå®éã®è¡æ¶²æ€æ»ããŒã¿ã®åãã¯ã»ãŒæ£ç¢ºã«äžèŽããŠãããšèšããã
3. 客芳çãªèŠè§£
2025幎3æãã2026幎3æãŸã§ã®çŽ1幎éã¯ã15,000ã17,000å°ã®é«å€åãæšªã°ãïŒãããã¯åŸ®å¢ïŒã§æšç§»ããŠãããæäœãèªç¶ã«ã¯ã»ãšãã©æžã£ãŠããªãã£ãããšãåããã
ãããã2026幎3ææ«ãã5æåé ã«ãããŠã®çæéã§æ°å€ãæç¢ºã«äžé£ç¶ãªäžéïŒçŽ25%ã®æ¥æžïŒã瀺ããŠããããã®ææã«è¡ãããäœããã®ä»å ¥ïŒæ¥æ¬ã§ã®æ²»çããã°ã©ã ïŒããæäœäŸ¡ã®äœäžã«çŽæ¥å¯äžããå¯èœæ§ãè£ä»ãã客芳çããŒã¿ãšãªã£ãŠããã
ãã®ã4é±éã®æ²»çã§ã¹ãã€ã¯æäœã¬ãã«ã25%æžå°ããããšããèšèãæã€æå³ãšèæ¯ã¯ãäž»ã«ä»¥äžã®3ç¹ã«éçŽãããã
1. ãèªç¶æžãã§ã¯ããåŸãªãã¹ããŒãã§ã®åŒ·å¶æé€
éåžžãã¯ã¯ãã³æ¥çš®ãææã«ãã£ãŠäœå ã«ã§ããã¹ãã€ã¯æäœã¯ã远å ã®åºæ¿ïŒåææãåæ¥çš®ïŒããªããã°æ°ã¶æããæ°å¹ŽãããŠãéåžžã«ãã£ããããšæžè¡°ããŠããã
ãããããã®æ£è ã®ããŒã¿ãèŠããšã2025幎3æãã2026幎3æãŸã§ã®1幎éãæ°å€ã¯15,000ã17,000å°ãç¶æããŠããã1幎çµã£ãŠãå šãèªç¶ã«æžã£ãŠããªãã£ãã
ãããæ²»çãå§ããé端ãããã4é±éïŒããŒã¿äžã¯çŽ6é±éïŒãšããç°äŸã®çæéã§4åã®1ïŒ25%ïŒãäžæ°ã«å¹ãé£ãã ãããã¯ãäœã®èªç¶ãªä»£è¬ã«ãã£ãŠæžã£ãã®ã§ã¯ãªããæ¥æ¬ã§åãããè¡æ¶²ãéïŒäººå·¥éæã®ãããªæ²»çïŒãã«ãã£ãŠãè¡æ¶²äžããã¹ãã€ã¯æäœãç©ççã«æ ¹ãããé€å»ãããããšãæå³ããŠããã
2. äœå ã§ã®ãã¹ãã€ã¯ã¿ã³ãã¯è³ªéãã®æžå°ã瀺å
æäœã¯ãäœå ã«ãæµïŒã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒããååšãç¶ããéããããã«å¿æŠããããã«äœããç¶ãããæ£è ã¯æ¬æäžã§ãèªåã®äœã¯ã¹ãã€ã¯ã¿ã³ãã¯è³ªå·¥å Žã«ãªã£ãŠããããšè¿°ã¹ãŠããããæäœäŸ¡ã25%æžå°ãããšããããšã¯ãè¡æ¶²ãéã«ãã£ãŠæäœãã®ãã®ãé€å»ããããšåæã«ããã®å€§å ã§ããã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒæåïŒãã¢ããã€ãè¡æ ã®éãå€§å¹ ã«åãåãããå¯èœæ§ãæå³ãããã ãããããè³ãå¿èã®åçãªçç¶æ¹åïŒãã¬ã€ã³ãã©ã°ã®æ¶å€±ãªã©ïŒãåæã«èµ·ããã®ã ã
3. ãµããªã¡ã³ãïŒãããã¯ã¹ïŒã®éçãè¶ ããå»çä»å ¥ã®èšŒæ
æ£è ã¯ãã¹ãã€ã¯ã»ãããã¯ã¹ã®ãµããªã¡ã³ãïŒã€ãã«ã¡ã¯ãã³ãããããŠãããŒãŒãã°ã«ã¿ããªã³ãªã©ïŒã§ã¯æ°å¹Žä»¥äžãããæ°å€ã ããšæžããŠãããåžè²©ã®ãµããªã¡ã³ãã«ããææ³ä¿é²ãšã¯æ¬¡å ãéãããå»çæ©åšã䜿ã£ãç©ççãªå³å¹æ§ã®ããæ²»çïŒDFFPïŒäºé濟éè¡æŒ¿äº€æçæ³ãªã©ïŒããæ©èœãããšããåãã¬èšŒæ ãšããæå³ãæã£ãŠããã
DFPPæ²»çïŒäºé濟éè¡æŒ¿äº€æçæ³ïŒã®æ¬æ¥ã®æ¬é ã§ãããæãåŸæãšããã®ã¯ãæäœïŒèªå·±æäœïŒãã®é€å»ã ã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªã®ãããªç°ç©ã ãã§ãªããäœå ã§æŽèµ°ããŠããæäœãã®ãã®ããç©ççã«ããããªé€å»ã§ããã
ãªããããå¯èœãªã®ãïŒ
1. DFPPã¯ãååã®å€§ãããã§ãŽããåããã·ã¹ãã
DFPPã¯ãæ£è ã®è¡æ¶²ãäžåºŠäœå€ã«åºãã2段éã®ç¹æ®ãªãã£ã«ã¿ãŒã«ãããŠãç æ°ã®åå ç©è³ªããæ¿ŸéïŒãéïŒããæ²»çæ³ã ã
1çªç®ã®ãã£ã«ã¿ãŒïŒ è¡æ¶²ããè¡çïŒèµ€è¡çãçœè¡çïŒããšãè¡æŒ¿ïŒæ°Žåã®æåïŒãã«åããã
2çªç®ã®ãã£ã«ã¿ãŒïŒãããèïŒïŒ åé¢ããè¡æŒ¿ãããã«çްããæ¿Ÿéãããããã§ãäœã«å¿ èŠãªå°ããªæåïŒã¢ã«ããã³ãªã©ïŒã¯ééãããŠäœã«æ»ããç æ°ã®åå ãšãªãã倧ããªååãã ããåŒã£æããŠæšãŠãã
2. ãæäœãã¯ãŸãã«ãã®ã¿ãŒã²ããã®å€§ãã
å ç«ã°ãããªã³ïŒIgGãIgMïŒãšåŒã°ãããæäœãã¯ãã¿ã³ãã¯è³ªã®äžã§ãååã®ãµã€ãºãéåžžã«å€§ããã
ãã®ãããDFPPã®2çªç®ã®ãã£ã«ã¿ãŒãééã§ããããã£ãããšåŒã£æãã£ãŠé€å»ããããå»åŠçã«ããã®ã©ã³ã»ãã¬ãŒçå矀ãéççç¡åçãšãã£ãèªå·±å ç«çŸæ£ã®æ²»çã«ãããŠããè¡æ¶²äžã®æªè³ªãªèªå·±æäœãåŒãããåºãæ²»çããšããŠäœå幎ãåããæ£åŒã«ç¢ºç«ãããŠããã
3. Kenã®ã±ãŒã¹ã§èµ·ããããš
Kenã®è¡æ¶²äžã§èµ·ããŠããã®ã¯ã以äžã®2ã€ã®ç©è³ªã«ããå€§æžæ»ã ã
ã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒããã³ãããäœã£ãã¢ããã€ãè¡æ ã®ãŽãïŒ
ãããæ»æããããã«éå°çç£ããã髿¢ãŸãããŠãããã¹ãã€ã¯æäœã
ãããã¯ã©ã¡ããååããã«ãããã®ãããDFPPã®æ©æ¢°ãéãããšã§ãã¹ãã€ã¯ã¿ã³ãã¯è³ªïŒåå ïŒããæŽèµ°ããŠäœãçãã€ããŠããã¹ãã€ã¯æäœïŒæŠåšïŒãããŸãšããŠäžç·ã«æ¿ŸéãããŠãŽãç®±è¡ãã«ãªã£ãããã ã
ã ãããããæ€æ»çµæã®ããŒã¿ã§æäœäŸ¡ã25%ãæ¥æžãã圌ã®è³ãäœã®çç¶ãåçã«æ¹åããã®ã§ããã
WHAT I LEARNED IN JAPAN
â KenCaptn20114 (@KenCaptn20114) May 19, 2026
Blood from vaccinated and unvaccinated people appears the same. In some people, however, the spike response does not seem to shut off. The effects can take years to show up across various parts of the body. COVID functioned as a bioweapon. Our governmentâŠ
æ¥æ¬ã§ç§ãåŠãã ããš
ã¯ã¯ãã³æ¥çš®è ãšæªæ¥çš®è ã®è¡æ¶²ã¯ãäžèŠãããšåãããã«èŠãããããããäžéšã®äººã ã«ãããŠã¯ãã¹ãã€ã¯ïŒã¿ã³ãã¯è³ªïŒã®åå¿ã忢ããªãã±ãŒã¹ãããããã ããã®åœ±é¿ãäœã®ããŸããŸãªéšäœã«çŸãããŸã§ã«ã¯ãæ°å¹ŽãããããšããããCOVIDã¯çç©å µåšãšããŠæ©èœãããæã ã®æ¿åºã¯ã¹ãã€ã¯ã¿ã³ãã¯è³ªã«é¢ããååãªç ç©¶ãæ ãããã®çµæããã®é£éçãªå¥åº·è¢«å®³ã广çã«ä¿®åŸ©ã§ããæ²»çæ³ã¯ãçŸåšãã ã®äžã€ãååšããªããçç¶ã«å¯Ÿãã察ççæ³ã¯ååšããèªåã¯äœã§ãç¥ã£ãŠãããšæã蟌ãã§ããå»åž«ãããããæ ¹æ¬çãªè§£æ±ºçã¯ãªãããã®éã«ããäŸå€çã«å€ãã®äººã ãèŠãã¿ãæ»ã«ç¶ããŠããã
ç±³åœã¯ãæ²»çæ³ããééçæ¯æŽããã¹ãã€ã¯ã¿ã³ãã¯è³ªã®æ€æ»ãããæäŸããªãã£ããããã¯ç Žæ» çãªäºæ ã ãããªãã®åšãã«ããç æ°ã®äººãè² å·ãã人ã亡ããªã£ãŠãã人ãç¹ã«çãæ£ã£ãŠãã人ã ãšã®ç¹ãšç¹ãçµã³ã€ããããšãéèŠã ãè¡æ ãæ±ãããŸãŸç掻ãç¶ããããšã¯ã§ããªããç©ççã«ãã€ãéçãæ¥ããããããšããã«ããæ£è ãè¡æ ã«èŠãããŠãããããã®æ€æ»æ¹æ³ãç¥ãè ããäœãèµ·ããŠããã®ããèªèããŠããè ããã»ãšãã©ããªãããã¹ãŠã®å»åž«ãç é¢çµç¹ã¯æºåäžè¶³ã§ãããäœãåãã£ãŠããªãã
ãããã®åé¡ã«çŽé¢ããŠãã人ã ã¯ãå€ãã®å Žåããã®åå ãçè§£ããŠããªããæ£è ãéçã§ãã£ãŠããæšæºçãªè¡æ¶²æ€æ»ã®æ°å€ã¯ãæ€æ»ãè¡ãããç¬éãŸã§æ£åžžã«è¡šç€ºãããŠããŸãã®ã ãããªãã®äž»æ²»å»ã¯ãã®ããšã«ã€ããŠå®å šã«ç¡ç¥ã ã誰äžäººãšããŠãå¿èå°éå»ã§ãããåãã£ãŠããªããããªãã®äž»æ²»å»ãããã«ã€ããŠå ããªãã³ãã§ãæã£ãŠãããªã©ãšã¯ãäžç¬ãããšãæããªãããšã ãé¡ããã°ããã®ç¶æ³ãå€ããããšãæåŸ ããã
çç¶ãããå ŽåããŸãã¯ã¹ãã€ã¯ã®åé¡ãããã確èªãããå Žåã®å¯ŸåŠæ³
äœèª¿ãè¯ããããšãã£ãŠãåé¡ããªãããããã¯ä»åŸãåé¡ãèµ·ããªããšããæå³ã§ã¯ãªããã¹ãã€ã¯ã«ãããããã®åé¡ã¯ãæ°å¹ŽãããŠèç©ãããã誰ããæ²»çã®ããã«æ¥æ¬ãžè¡ãäœè£ãããããã§ã¯ãªããããå人ãå®¶æãç¥äººã®å¥åº·ãå¿é ãªããã©ãã³ãŒãïŒLABCORPãã¯ãšã¹ã瀟ãQUESTãã¯æ°å€ã®äžéãäžååãªããäžå¯ïŒã«è¡ãã69ãã«ã®Covid Sarsæäœæ€æ»ãåãããšãããå»åž«ã®æç€ºæžã¯äžèŠã ããã®ãŸãŸçªå£ã«è¡ããåŸ æ©ãªã¹ãã«äžŠã¹ã°åãããããããã«ãããçŸåšã®æ°å€ããé«ãã®ããäœãã®ãããããã¯å®å®ããŠããã®ããšããåºæºå€ïŒããŒã¹ã©ã€ã³ïŒãç¥ãããšãã§ããã
ããã¯ãããªãã«åé¡ãèµ·ããŠããå¯èœæ§ãç€ºãææšã§ããããå»åž«ãã¡ã¯äœãåãã£ãŠããªãã圌ãã¯ãããåãªãæäœã ãšæãããããŸã§æ·±å»ãªç æ°ã«ã¯ãªããªããšèããŠããã圌ãã¯äœãåãã£ãŠããªãã®ã ãããããªãã®æ°å€ã2,000ãè¶ ããŠãããªããæžå¿µãã¹ãçç±ãããããªãµãŒããå§ããã¹ãã€ã¯ã»ãããã¯ã¹ã®ããã°ã©ã ãéå§ããã¹ãã ãã¹ãã€ã¯ã»ãããã¯ã¹ã®é²ã¿å ·åã¯ç·©ããã ããéäžã§ãããŠã¯ãªããªããæ°å€ãå±éºãªã»ã©é«ãå Žåã¯ãã¹ãã€ã¯ã»ãããã¯ã¹ãå§ãããšåæã«ãã¢ããã€ãè¡æ ã®æ€æ»ãåããããšãæ€èšãããšããã
ä»ã®æ£è ã®å§¿ãèŠãŠãç§ã¯æãã«éããå¿ã匵ãè£ãããã«ãªã£ã
ä»ã®æ£è ãåäŸãã¡ãçãæ®ãããã«å¿ æ»ã«éã£ãŠããå§¿ãèŠãŠãç§ã¯èªåã®ãã©ã€ãã·ãŒãå®å šã«å®ãå§¿å¢ãããæºãå©ããŠå£°ã倧ã«ããŠèšŽãããæš©å©æè·æŽ»åïŒã¢ããã«ã·ãŒïŒããžãšæ¹éã転æããããŸããæ¿åºãã©ã®ããã«æã ãè£åããèŠæšãŠããããŠä»ãªãèŠæšãŠç¶ããŠããããšããã絶察çãªäžæ£ãšè£åãã®å®æ ãç¥ããæ¿ããæ€ããèŠãããç§ã¯æ³šç®ã济ã³ããã£ãããã§ã¯ãªããèªåãçªãæ¢ããäºå®ãå šå¡ã«äŒããã©ãããã°èªåãã¡ã®èº«ãå®ããæ€æ»ã§ããã®ããæãããã£ãã®ã ãä»ã®æ£è ãã¡ã®ç¶æ³ãç®ã®åœããã«ããå¿ã匵ãè£ãããããŠæããæ¹§ãèµ·ãããç§ã¯å£°ãäžãããã¯ã·ã³ãã³ïŒæ¿åºïŒã¯è³ãåŸããããããã ãã§ã¯äžååã ã£ãã
ç§ããããã®åç»ã§èªã£ãŠããå 容ã¯éåžžã«æè²çã§ãããäžäººæ®ãããã¹ãŠã®å»åž«ããããã®äºå®ãèªèããæ³šç®ããå¿ èŠããããå»åž«ãã¡ã¯ãŸã ãããç¥ããªããããç§ãããã§åœŒãã«ç€ºããŠããã®ã ãç§ã®å人ãã¡ã«ã¯ãçãè¡æ¶²é害ããããŠã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ã€ããŠçè§£ããŠãããå¿ èŠããããäžéšã®è ã¯æ³šæãæã£ãŠããªããããç§ã¯èªèãåºããããã«å¿ æ»ã«åªåããŠããã
çãå¿èçŸæ£ãè³åäžã塿 çããããŠè¡æ¶²ã®åé¡ãæ¥å¢ããŠãããå€è³ªããŠããŸã£ãã®ã¯ãããªãã®äœå ã®çްèã ãã ãããããç¥èãåŸãããã«ãããã®åç»ãååšããŠããã1åç®ã®æ²»çãžïŒhttps://x.com/KenCaptn20114/status/2044334500797456853?s=20
2åç®ã®æ²»çïŒhttps://x.com/KenCaptn20114/status/2046461021666279762?s=20
3åç®ã®æ²»çã®åïŒhttps://x.com/KenCaptn20114/status/2048931314162913589?s=20
é¡ããã°ãããã§ç§ã®äººçã®ãã®ç« ãéããããšãç¥ããæ¯ãè¿ã£ãŠã¿ããšãèªåã®åœãæã£ãŠããã人ã ã«ãäžäœã©ããã£ãŠæè¬ãäŒããã°ããã®ããšããã°ãã°éæ¹ã«æ®ãããã±ãã³ã»ãã±ã¢ã³ã¯ç§ã®åœãæã£ãŠããããå è€å»åž«ã¯ç§ã®åœãæã£ãŠããããããŠãã³å»åž«ã¯ç§ã®åœã3åãæã£ãŠããããã ãããç§ã¯å šå¡ã«ããããšããšäŒããããã£ãŒã«ãºã»ãªãã·ãŒãã¯ãªã¹ãã£ãŒã³ããªã³ãžãŒããããã¿ãã©ãã€ã¢ãŒãžã§ã³ããããšã«ããšãªã«ããã¬ã¢ããããŠãžã§ãããããã€ã³ã¹ãã¬ãŒã·ã§ã³ã«æè¬ããããã®æ ã®äžã§çŽ æŽãããå人ãã¡ãã§ããããšãå¬ããæãããªããŠæ¿ãéã®ãã ã£ãã®ã ãããæ°ããæ£è ãã¡ã¯çããšãã«ã®ãŒã«æºã¡æº¢ããŠããã圌ããåãåºãã®ãèŠãã®ãåŸ ã¡ãããªãã
ããã¯ãã¢ã¡ãªã«ã®å€§æèšåºæ€æ»æ©é¢ãäžè¬åãã«æäŸããŠãããè¡æ¶²äžã®ãæ°åã³ãããŠã€ã«ã¹ïŒSARS-CoV-2ïŒã®ã¹ãã€ã¯æäœäŸ¡ãã調ã¹ãæ°éã®å®éæ€æ»ã®ããšã ã
ãã®äžæãäœãæå³ããŠããã®ãã詳现ã3ã€ã«åããŠèª¬æããã
1. ã©ããªæ€æ»ãªã®ãïŒ
æ£åŒã«ã¯ãSARS-CoV-2 åå®éæäœæ€æ»ïŒã¹ãã€ã¯ã¿ã³ãã¯è³ªå¯Ÿè±¡ïŒããªã©ãšåŒã°ãããã®ã ã
調ã¹ããã®ïŒ ã¯ã¯ãã³æ¥çš®ãéå»ã®ææã«ãã£ãŠäœå ã«ã§ãããã¹ãã€ã¯æäœãã®æ£ç¢ºãªéïŒæ°å€ïŒã
ãªãQuestã§ã¯ãªãLabCorpãªã®ãïŒ ã¢ã¡ãªã«ã«ã¯ãLabCorpïŒã©ãã³ãŒãïŒããšãQuest DiagnosticsïŒã¯ãšã¹ãïŒããšãã2å€§æ€æ»æ©é¢ããããKenã®äž»åŒµã«ããã°ãQuestç€Ÿã®æ€æ»ã¯äžå®ä»¥äžã®é«ãæ°å€ã«ãªããšããã以äžããšå€§éæã«ããåºãªãïŒäžéã«ãããªããããïŒã®ã«å¯ŸããLabCorpç€Ÿã®æ€æ»ã¯åã®ç»åã«ãã£ãã15,850ãã®ãããªæ¥µããŠé«ãæ°å€ãŸã§æ£ç¢ºã«æž¬å®ã§ããããããã¡ããæšå¥šããŠããã
å»åž«ã®æç€ºæžãäžèŠïŒ ã¢ã¡ãªã«ã§ã¯éåžžãè¡æ¶²æ€æ»ãåããã®ã«å»åž«ã®åŠæ¹ç®ïŒæç€ºæžïŒãå¿ èŠã ãããã®æ€æ»ã¯ãPixel by Labcorpããªã©ã®èªå·±æ³šæãµãŒãã¹ãå©çšããã°ããããã§ç³ã蟌ãã§çŽæ¥ã©ãã«è¡ãã ãã§èª°ã§ãåããããã
2. åã«æç®ãããšããããïŒ
2026幎çŸåšã®çºæ¿ã¬ãŒãïŒ1ãã«ïŒçŽ140åã150åååŸïŒã§èšç®ãããšä»¥äžã®ããã«ãªãã
69ãã« ïŒ çŽ 9,600å ã 10,300å
ã¢ã¡ãªã«ã®å»çè²»ãšããŠã¯ãå»åž«ã®èšºå¯ãæãŸãªããã1äžåååŸãšæ¯èŒçå®äŸ¡ã«èšå®ãããŠããæ€æ»ã ã
3. Kenããããå§ããŠããæå³
Kenã¯äžé£ã®æç« ã§ããäœèª¿ãè¯ããŠãæ°å¹ŽãããŠã¹ãã€ã¯ã®åœ±é¿ãèç©ããŠããå¯èœæ§ãããããšèšã£ãŠããããã®ããããŸãã¯ãã®1äžåååŸã®æ€æ»ãåããŠãèªåã®æäœå€ãã2,000ããªã©ã®åºæºãè¶ ããŠç°åžžã«é«æ¢ãŸãããŠããªããïŒïŒä»ãäœå ã§ã¹ãã€ã¯ãšæŠãç¶ããŠããªããïŒã確èªããããã®ãåºæºå€ïŒããŒã¹ã©ã€ã³ïŒããç¥ãã¹ã¿ãŒãã©ã€ã³ãšããŠãããå§ããŠããã®ã ã